Your SlideShare is downloading. ×
Clinimacs Newsletter 2010
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Clinimacs Newsletter 2010

2,511
views

Published on

Published in: Technology, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,511
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. II Customer report Newsletter Vol. 10 No. 1/2010 CliniMACS® Poster report Poster report from the ASBMT 2010, USA Products and applications MACS® GMP Products Meeting minutes ESC 2009, ASH 2009, EBMT 2010
  • 2. 2 CliniMACS Newsletter 1/2010 CliniMACS Newsletter online: www.miltenyibiotec.com/en/NN_503_CliniMACS_Newsletter.aspx The CliniMACS® System components: Instruments, Reagents, Tubing Sets, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS® MicroBeads are for research use only and not for use in humans. MACS GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. The CryoMACS Freezing Bags are manufactured by Miltenyi Biotec GmbH and controlled under an ISO 13485 certified quality system. These products are available in Europe as CE-marked medical devices and are marketed in the USA under FDA 510(k) clearance. CliniMACS and MACS are registered trademarks and TheraSorb is a trademark of Miltenyi Biotec GmbH. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2010 Miltenyi Biotec GmbH. All rights reserved. The CliniMACS® Newsletter is published by Miltenyi Biotec GmbH. Editors: Dr. Dirk Balshüsemann, Shamala S. Palaniappan Editorial board: Heike Lahnor, Dr. Michaela Malchow, Dr. Petra Bauer, Dr. Martina Simon, Dr. Katja Petry, Dr. Silke Schnell-Coopmans, Dr. Nanette von Oppen Graphics & Layout: Miltenyi Biotec GmbH. Miltenyi Biotec GmbH, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany. Phone +49 2204 8306-0, e-mail: macs@miltenyibiotec.de. 4 Poster report Poster report from the 2010 annual meeting of the American Society for Blood and Marrow Transplantation (ASBMT) in Orlando, Florida, USA 7 Products and applications MACS® GMP Products Blood dendritic cells 11 Meeting minutes ESC 2009 ASH 2009 EBMT 2010 22 Frequently asked questions 26 Conference calendar 27 Fax reply form In this issue Contents
  • 3. 3 Editorial Editorial Dear Colleagues, I am pleased to present the latest issue of our CliniMACS® Newsletter. At Miltenyi Biotec it has been our focus, for many years, to offer innovative products for biomedical and preclinical research. Within just over twenty years since the company began, this has resulted in over 1,000 products for cell separation, analysis, cell culture, and molecular characterization. Close co-operations and numerous contacts with researchers all over the world have enabled our scientists to stay tuned to the latest developments in areas of biomedical research with potential for improved cellular therapies. The requests and advice from translational as well as clinical researchers are the key to our efforts to bring innovative treatment concepts ‘from bench to bedside’. In this respect, we are proud to announce that recently several MACS® GMP Products have been added to our clinical grade product portfolio. These products include GMP Cytokines for cultivation and differentiation of cells and GMP Antigens—as recombinant protein or peptide pool—for efficient in vitro stimulation andsubsequentisolationofviableantigen-specific T cells. Read more on page 7. Research into regulatory T cells (Tregs) has been one of the key topics in immunology during recent years. It was found that these immunomodulatory cellsplayanimportantroleincelltherapyconcepts for tolerance induction. Today, in the context of haploidentical transplantation, Tregs are already under clinical evaluation. The rationale is to allow infusion of donor T cells for improved immune reconstitution without increasing the risk of GvHD. In this issue, you will find the summary of a presentation from the recent ASH meeting describingthisapproach.Highlightsandabstracts are on page 15. Results of a US multicenter trial (BMT CTN protocol 0303), which investigated the use of T cell–depleted grafts after myeloablative conditioning for acute myeloid leukemia, were presented at the same ASH meeting. The investigators did not find an increased rate of relapses despite the profound T cell depletion, but they did find a remarkable reduction in acute and chronic graft-versus-host disease. As in previous years, we hosted a satellite symposiumattheannualmeetingoftheEuropean Society of Cardiology in Barcelona, Spain. Several trials were presented in that session and we are particularly proud of having started the first phase III trial investigating the effects of autologous bone marrow–derived stem cells in cardiac disease. An excerpt is on page 12. Finally, I would like to draw your attention to the list of upcoming congresses and symposia on page 26. Take the opportunity to meet us there and to discuss your recent findings and future plans in cellular therapy! With kind regards, Dr. Dirk Balshüsemann Miltenyi Biotec GmbH
  • 4. 4 CliniMACS Newsletter 1/2010 Poster report Introduction Thisposterreporttiesupdatapresentedforthefirst time by Richard O’Reilly at the annual meeting of the American Society of Hematology (ASH) 2009 in New Orleans, Louisiana, USA. At ASH, the results were shown from the BMT CTN protocol 0303 phase II multicenter trial which utilized a uniform technique of CD34+ selection with the CliniMACS device in adult patients with AML in first or second complete remission (refer to page 15). The outcome data of 44 patients demonstrated that infusion of CD34- enriched stem cells from a matched, related donor resulted in low transplant-related mortality, low incidence of relapse, and low incidences of graft- versus-host disease (GvHD) in the absence of any post-transplantprophylaxis,whiledisease-freeand overall survival were excellent. For this poster, the authors compared their BMT CTN protocol 0303 trial with the concomitant BMT CTN protocol 0101 phase III multicenter trial, whose aim was the comparison of two antifungal prophylaxis medications after allogeneicTcell–depletedstemcelltransplantation with pharmacologic immunosuppression, post transplantation. Using the same eligibility criteria from BMT CTN protocol 0303 trial as selection criteria for the protocol 0101 patient population, 102 patients from the latter trial were selected as controls for the protocol 0303 trial. Outcomes were assessed after 6 and 12 months of follow-up (refer to table 1) and included disease-free survival (DFS), overall From the poster board: Poster report from the 2010 annual meeting of the American Society for Blood and Marrow Transplantation (ASBMT) in Orlando, Florida, USA In: Biol. Blood Marrow Transplant 2010, 16: S268 (abstract 297) Comparative effectiveness analysis of CD34+ selected, T cell–depleted (TCD), HLA-matched sibling grafts on allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia (AML) in complete remission. Presented by Pasquini M. et al., on behalf of the Blood and Marrow Transplant Clinical Trials Network. survival(OS),transplant-relatedmortality(TRM), and rates of acute and chronic GvHD. Relapse, DFS, OS, and TRM were similar in both cohorts. However, there was a notable difference in the rates of GvHD between the two cohorts. For acute GvHD the TCD group showed a rate of 20% versus 38% in the non-TCD group at 100 days post-transplant. The difference in the occurrence of chronic GvHD was even more significant: 19% versus 47% at one year after transplantation. With this comparative analysis the authors found similar outcomes in TCD and non-TCD sibling allografts in AML, and showed that a standardized approachtoTcelldepletionissafeandreproducible, and leads to a reduction in debilitating GvHD without increasing relapse rates. The fact that this reduction was achieved in the absence of any post-transplant immune suppression suggests that patients receiving CD34-selected TCD grafts will enjoy an improved quality of life. Inconclusion,thesedatasupportTcelldepletionin the matched setting and suggest its extension to the matched unrelated setting.
  • 5. 5 Poster report Outcome TCD [%] (95% CI) n=44 non-TCD [%] (95% CI) n=102 p-value Disease-free survival at 6 months 81 (66–90) 75 (68–87) NS Relapse at 12 months 19 (6–32) 19 (11–26) NS Transplant-related mortality at 12 months 19 (6–31) 22 (14–30) NS Engraftment at 28 days 100 (86–100) 90 (79–100) NS Acute GvHD II-IV at 100 days 20 (9–32) 38 (28–47) 0.046 Chronic GvHD at 12 months 19 (7–32) 47 (35–58) 0.008 Overall survival at 12 months 74 (57–85) 69 (59–77) NS Figure 1: Acute GvHD at 100 days post-transplant. Table 1: Follow-up data for 6 and 12 months. NS = not significant. Figure 2: Chronic GvHD at one year post-transplant. Acute GvHD at 100 days post transplant 0 5 10 15 20 25 30 35 40 non-TCD TCD Probability (%) Chronic GvHD at 1 year post transplant 0 5 10 15 20 25 30 35 40 45 50 non-TCD TCD Probability (%) 0 5 10 15 non-TCD TCD Probability (%) Chronic GvHD at 1 year post transplant 0 5 10 15 20 25 30 35 40 45 50 non-TCD TCD Probability (%) Probability(%) Probability(%)
  • 6. 6 CliniMACS Newsletter 1/2010 Customer report • MACS GMP Antigens • MACS GMP Media • MACS GMP Cytokines • CE-marked cell expansion and differentiation bags MACS GMP Cytokines, MACS GMP Media, and MACS GMP Antigens are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. The products are manufactured and tested under a certified ISO 9001:2000 quality system and in compliance with relevant GMP guidelines and the recommendations of USP chapter 1043 on ancillary materials. In the USA, Cell Culture Bags are available for research use only. MACS is a registered trademark of Miltenyi Biotec GmbH. Copyright © 2010 Miltenyi Biotec. All rights reserved. Advancements in clinical application MACS® GMP Products Miltenyi Biotec provides products and services worldwide Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact. www.macsgmp.com
  • 7. 7 Customer report Advancements in clinical applications MACS® GMP Products MACS GMP Products enhance therapeutic procedures through cell stimulation, cell expansion and differentiation, and cryopreservation. Introduction Cell-based therapies are an emerging treatment option in a variety of diseases, for example, solid tumors, hematologic malignancies, and transplantation-related complications. The basis for the increase of therapies arises from an improved understanding of cellular function and culture of precursor cells like monocytes. The understanding of the plasticity of these precursor cells allows maturation and manipulation of cells in vitro. Miltenyi Biotec provides a range of solutions to support the manufacturing process of cell-based therapies. From the core process to additional steps, we have systems and GMP Products to enhance the therapeutic procedure through: 1. Cell stimulation It may be necessary to stimulate the cells between leukapheresis and cell separation. Our range of MACS GMP Antigens, Cytokines, Media, and Cell Culture Bags offers an ideal platform to complete the process. 2. Cell expansion and differentiation The same products are also used for cell expansion and differentiation, which may be performed after cell separation. 3. Cryopreservation CryoMACS® Freezing Bags offer the option for cryopreservation after leukapheresis or prior to administration to the patient. Quality: crucial in advancing clinical applications The quality of the starting materials dramatically influences the outcome of the cellular product. All MACS GMP Products are manufactured in our state-of-the-art GMP facility in Teterow, Germany in standardized and strictly controlled industrial processing steps. They are designed according to the recommendations of the United States Pharmacopeia, chapter 1043 on ancillary materials for cell-, gene-, and tissue-engineered products. Consequently, they are free of human and animal-derived components, and product specifications are confirmed by batch-specific certificates of analysis to ensure consistency of quality. MACS GMP Products MACS GMP Antigens MACS GMP Antigens are designed for in vitro stimulation of antigen-specific T cells and for antigen loading of dendritic cells (DCs). MACS GMP Antigens are offered in two different configurations: as a recombinant protein in its natural configuration, or as a peptide pool (PepTivator®) consisting of mainly 15-mer peptides, covering the whole sequence of the antigen. Both products efficiently stimulate CD4+ and CD8+ T  cells in vitro and cause the production of the effector cytokine IFN-γ by the antigen-specific T cells. IFN-γ secretion permits enrichment of antigen-specific effector/memory T cells by using CliniMACS Cytokine Capture System (IFN‑gamma). The viral antigens pp65 (HCMV) and hexon (AdV) are offered as MACS GMP Products and our MACS GMP Antigen product portfolio is constantly growing. MACS GMP Cytokines MACS GMP Cytokines are recombinant human cytokines for research applications or ex vivo cell culture, for example, the ex vivo generation of human DCs from enriched CD14+ monocytes. MACS GMP Cytokines are lyophilized without carrier protein or preservatives. Reliable reconstitution and performance is assured by an optimized formulation. Lot-specific certificates confirm identity, molecular mass, specific activity, sterility, purity, and endotoxin content, as well as host-cell DNA and protein content. MACS GMP Recombinant Human IL-4, GM-CSF, IL-1β, TNF-α, and IL-6 constitute a comprehensive portfolio of cytokines for ex vivo DC generation. Products and applications
  • 8. 8 CliniMACS Newsletter 1/2010 Products and applications For additional applications, IL-3 and FGF-2 are already available and IL-2, IL-7, and IL-15 will soon expand the fast-growing range of MACS GMP Cytokines. MACS GMP Media MACS GMP Media are serum-free, defined formulations optimized for cultivation and expansion of cells ex vivo. The high quality DendriMACSTM Medium has been designed for optimal and standardized cultivation of human DCs and the generation of monocyte-derived DCs from CD14+ monocytes. MACS GMP Media are manufactured without phenol red and are supplied in bags. A tailored medium for optimal cultivation and expansion of human T and regulatory cells will follow soon. Cell Culture Bags CE-marked Cell Culture Bags were developed for in vitro culture, differentiation, and expansion of human cells from heterogeneous hematologic cell populations in a functionally closed system. The unique Cell Expansion Bag has a compartmentalized culture chamber with two easy-to-open seals. This allows for expandable culture volume as cell numbers increase during culture period. There is no need to change the culture vessel, which reduces the risk of contamination. Cell Expansion Bags for volumes up to 100 mL are on offer. Also available are Cell Differentiation Bags with one culture chamber. They come in three different volumes (100, 250, and 500 mL). Volumes of 1,000 and 3,000 mL will be available soon.
  • 9. 9 Products and applications DC-based immune therapy Due to their key role in initiation and regulation of innate and adaptive immune response, dendritic cells (DCs) are widely used in clinical trials to induce effective anti-tumor immunity—with moderate efficacy.1 Recently, however, a double- blind, placebo-controlled phase III study in advanced prostate cancer was able to show extended median survival after vaccination with autologous tumor-antigen-loaded, antigen- presenting cells (APCs).2 Remarkably, in contrast to most other DC-based studies, in which ex vivo- generated, monocyte-derived DCs (MoDCs) had been used, in this case APCs were directly isolated from blood. Properties of the native cells and the combination of different APCs may be the key to success. Distinct DC subsets in blood Two major populations of DCs are distinguished in human peripheral blood, myeloid DCs (MDCs) and plasmacytoid DCs (PDCs). The different subsets seem to be functionally specialized. Whereas MDCs, as MoDCs, have a strong T cell stimulatory capacity,3 PDCs are characterized by production of high amounts of type I interferon (IFN) after activation via Toll-like receptors (TLRs).4-6 Type I IFNs enhance innate and adaptive immune response by initiating a series of cellular events involving sequential activation of NK cells, B cells, monocytes, MDCs, and CD8+ T cells.7 PDCs are thus believed to be crucial for a strong and effective anti-tumor therapy.8 Pre- clinical experiments using tumor mouse models, inwhichPDCvaccinationresultedinregressionof treated and non-treated distant tumors, confirm this assumption.7,9 Pilot studies with blood DCs confirm safety and feasibility Recently, Figdor, de Vries, and co-workers performed the first phase I PDC vaccine study in late-stage melanoma patients. They proved safety and feasibility, and showed induction of an antigen-specific immune response.10 The promising immunological results will be published soon. Safety and feasibility of antigen- pulsed MDCs in clinical studies on the treatment of melanoma and prostate cancer was shown earlier.11,12 Direct isolation of blood DCs using the CliniMACS® System TheCE-markingofCliniMACSCD304(BDCA-4) Reagent has now extended the product line for clinical-scale enrichment of DCs in combination with the CliniMACS System. PDCs, as well as MDCs, can now be easily isolated directly from blood with high purity and reproducible yield, according to distinct expression of specific surface markers CD304 (BDCA-4) on PDCs and CD1c (BDCA-1) on MDCs.13 Using the CliniMACS Instrument, separation is performed in a closed, automated system. Remarkably, cells are immature upon isolation and mature overnight in culture. Long culture periods, as required for the differentiation and maturation of MoDCs, are therefore avoided. The opportunity to enrich PDCs and MDCs directly from blood in a clinical setting thus reveals new perspectives for DC-based immune therapy. References 1. Melief, C.J. (2008) Immunity 29: 372–383. 2. Higano, C.S. et al. (2009) Cancer 115: 3670–3679. 3. Jefford, M. et al. (2003) Blood 102: 1753–1763. 4. Liu, Y.J. (2005) Annu. Rev. Immunol. 23: 275–306. 5. McKenna, K. et al. (2005) J. Virol. 79: 17–27. 6. Schreibelt, G. et al.(2010) Cancer Immunol. Immunother. 59: 1573–1582. 7. Liu, C. et al. (2008) J. Clin. Invest. 118: 1165–1175. 8. Kim, R. et al. (2007) Immunology 127:149–157. 9. Aspord, C. et al. (2010) PLoS ONE 5: 10458–10458. 10. de Vries, I.J.M. et al. (2010) 11th International Symposium on Dendritic Cells (DC2010): Abstract #S05-003 11. Prue, R. L. et al. (2007) 5th Int. Meeting on DC vaccination (DC2007): Abstract #P090. 12. Davis, I. D. et al. (2005) Proc. Amer. Assoc. Cancer. Res. 46: Abstract #3466. 13. Dzionek, A. et al. (2000) J. Immunol. 165: 6037–6046. New perspectives for DC-based immune therapy: blood dendritic cells
  • 10. 10 CliniMACS Newsletter 1/2010 Customer report Product Application Availability Order no. Plasmacytoid dendritic cells – CliniMACS CD304 (BDCA-4) Cell Enrichment CliniMACS CD304 (BDCA-4) Reagent, CE Enrichment of CD304 (BDCA-4)+ PDCs in a clinical setting Europe1) 278-01 CliniMACS CD304 (BDCA-4) MicroBeads Enrichment of CD304 (BDCA-4)+ PDCs in a pre-clinical setting USA2) , CAN, AUS 291-01 Myeloid dendritic cells – CliniMACS CD1c (BDCA) Cell Enrichment CliniMACS CD1c (BDCA-1)/ CD19 Complete Kit, CE Kit contains all components needed for enrichment of CD1c (BCDA-1)+ MDCs in a clinical setting Europe1) 740-03 CliniMACS CD1c (BDCA-1)- Biotin for Research Use Enrichment of CD1c (BCDA-1)+ MDCs in conjunction with CliniMACS Anti-Biotin Reagent and CliniMACS CD19 Reagent for pre-clinical settings USA2) , CAN, AUS 255-01 1) Not available in the US. 2) In the US only for research use. Products and applications CliniMACS® Products for direct isolation of blood DCs The MACS® GMP Product portfolio for dendritic cells Product Order no. DendriMACS GMP Medium 170-076-302 MACS GMP Recombinant Human IL-3 170-076-110 MACS GMP Recombinant Human IL-4 170-076-101 MACS GMP Recombinant Human GM-CSF 170-076-112 MACS GMP Recombinant Human IL-1ß 170-076-102 MACS GMP Recombinant Human TNF-α 170-076-103 MACS GMP Recombinant Human Il-6 170-076-104 MACS GMP HCMV pp65 – Recombinant Protein 200-076-100 MACS GMP PepTivator HCMV pp65 170-076-109 MACS GMP PepTivator AdV5 Hexon 170-076-106
  • 11. 11 Meeting minutes Meeting minutes 2009/2010 ESC 2009, ASH 2009, EBMT 2010
  • 12. 12 CliniMACS Newsletter 1/2010 Meeting minutes Study design: Alster-MACS: Randomized study on the effect of CD133+´ stem cells in chronic ischemic cardiomyopathy delivered intracoronary or intramyocardially Martin Bergmann, Germany Treatment of cardiomyopathies with autologous bone marrow stem cells by the intracoronary or intramyocardial route has been shown to be safe. The efficacy of these treatments has been somewhat limited, however. Two strategies that might improve this effectiveness involve the identification of the most effective cell type and improvement in the route of administration. ESC 2009 August 29 to September 2, 2009, Barcelona, Spain Satellite symposium: Study concepts and routes of administration in autologous stem cell therapy. The following summary elucidates compiled information on surgical and interventional concepts to investigate autologous stem cell therapy approaches in cardiovascular diseases. Cellular therapy – present aspects Gustav Steinhoff, Germany The last ten years have been marked by new developments in the field of cardiac therapies, especially in cases of heart failure. One of those developments is the transplantation of autologous stem cells, although there are still many questions to be answered with respect to the source of the graft (blood, bone marrow, skeletal muscle, adipose tissue, embryonic stem cells), and the route of administration (local or systemic). It is also unclear whether bone marrow–derived cells should be used in an unmodified state or whether they should be enriched for the antigen133. There are considerable regulatory issues that have to be resolved before human trials can take place and these require investment of considerable time and effort before approval can be granted. This Satellite Symposium focuses on the application of CD133+ bone marrow stem cells in cardiac disease. “… identification of the most effective cell type and improvement in the route of administration.”
  • 13. 13 Meeting minutes Patients with refractory angina treated with peripheral blood–derived stem cells using the transendocardial injection route Pilar Jimenez-Quevedo, Spain A randomized, blinded, multicenter controlled trial has been designed to assess the safety and efficacy of transendocardial injection of selected CD133+ cells in patients with refractory angina without any option of standard revascularization. Patients will be treated with G-CSF for 4 days prior to leukapheresis and enrichment of CD133+ cells. Crossover will be carried out 6 months after the CD133+ cells have been administered by trans-endocardial injection with the aid of electromechanical cardiac mapping. The results of this study will shed light on the treatment of this subset of patients who still show symptoms despite maximum conventional therapy. A randomized, single-blinded, clinical trial has been designed to examine the efficacy of autologous CD133+ stem cells in the treatment of patients with chronic ischemic cardiomyopathy. The trial will compare the intracoronary route with the intramyocardial route with intensive follow-up for one year, and endpoints at 6 and 12 months. The endpoints will be assessed on global ejection fraction, cardiac performance, 6 minute– walk test and a quality of life questionnaire. “The aims of stem cell transplantation are to improve the level of neovascularization and to regenerate damaged myocardial tissue”. Intramyocardial transplantation of bone marrow stem cells for improvement of post-infarct myocardial regeneration in addition to bypass surgery: a controlled, prospective, randomized, double-blinded, phase III, multicentric trial (PERFECT trial) Gustav Steinhoff, Germany The preparation of CD133+ cells as a cell- based product should be standardized and the component cells characterized by, for example, flow analysis, preclinical models, and other phenotypic analyses. Previous phase I and II clinical trials of bone marrow stem cells in the treatment of chronic ischemia following cardiac infarction and subsequent coronary artery bypass grafting (CABG) have shown that there is a positive effect on left ventricle ejection fraction (LVEF) and improved survival compared to CABG alone; graft-relatedcomplicationswerenotobserved.The PERFECT trial is a phase III placebo-controlled, double blind, multicenter trial designed to investigate whether the intramyocardial injection of autologous, bone marrow-derived CD133+ cells results as a functional benefit for CABG patients. Onehundredandforty-twopatientswithcoronary artery disease after myocardial infarction, with an indication for CABG and LVEF values between 25% and 40%, will be enrolled in the study and randomized to either enriched autologous CD133+ stem cell or placebo. The study period is 6 months; LVEF assessed by magnetic resonance imaging (MRI) is listed as both primary and secondary endpoints. Secondary endpoints will include echocardiography, physical exercise testing, and a quality of life assessment. Recent evidence suggests that the heart can undergo repair processes in adulthood and that vasculogenesis may not be exclusive to embryonic development. Revascularization of tissue following a cardiac infarct is one of the aims of conventional therapy, although 12% of all patients referred to a coronary artery disease clinic are refractory to further revascularization because they have diffuse coronary disease, small distal vessels, recurrent stent stenosis, chronic total occlusion, or co-morbidities. Several secondary medicinal treatments are available but there is a lack of evidence that these have any benefit to the patient. Other treatment strategies, such as laser treatment or neurostimulation, are associated with inconsistent data in the clinical situation. “… there is a positive effect on left ventricle ejection fraction (LVEF) and improved survival compared to CABG alone; graft-related complications were not observed.” “The results of this study will shed light on the treatment of this subset of patients who still show symptoms despite maximum conventional therapy.” “Two strategies that might improve this effectiveness involve the identification of the most effective cell type and improvement in the route of administration.”
  • 14. 14 CliniMACS Newsletter 1/2010 Meeting minutes Intramyocardial application of stem cells in combination with transmyocardial laser revascularization in CABG patients Hans-Michael Klein, Germany as laser or shock wave treatment of the affected tissue, are required to improve functionality of the graft. A trial has recently been initiated that investigates intramyocardial injection of CD133+ cells purified by CliniMACS in MI patients with ejection fraction values between 15% and 35%. Preliminary results demonstrate improvements in cardiac function and quality of life. The 6 month follow-up shows a significant increase in LVEF measures by echocardiography. The MRI estimation of LVEF is more subject to variability, mainly as a result of patient excitability. It also appears that the level of scarring in the myocardial tissue has a negative effect on the outcome of stem cell therapy. Therearestillmanyquestionstobeansweredwhen considering stem cell treatment of the sequelae of myocardial infarction (MI). Hematopoietic stem cellsseemtobethemosteffectivetypeofcellbutthe question remains whether cell processing should be carried out parallel to surgery in the operating theater or in a separate laboratory. A further question concerns the route of administration: on the one hand, intravenous injection is clearly ineffective and intracoronary injection appears to have limited effectiveness. On the other hand, transendocardial and transepicardial injection during surgery appear to be equally effective. There is also some debate about whether intra- operative revascularization procedures, such Comparison of intracoronary CD133+ bone marrow stem cells to placebo in cardiac recovery after myocardial infarction Samer Mansour, Canada Although bone marrow stem cell grafts represent a promising approach to the treatment of the infarcted myocardium, use of heterogeneous preparations of bone marrow cells have led to variable clinical outcomes, possibly because the different cell types in the graft interfere with each other. Experimental evidence suggests a role for CD133/34+ stem cells in the biological repair of the damaged myocardium through their ability to enhance vasculogenesis and myocyte regeneration. A pilot trial of CD133+ stem cells administered by the intracoronary route resulted in an improvement in the LV ejection fraction in the treated patients when compared to controls matched for ejection fraction, size of infarct, and its localization. However, angiographic findings indicated an increase in restenosis in the treated group during the four month follow-up period so a double-blind, randomized, placebo-controlled trialwasdesignedtoinvestigatethesafety,efficacy, and functional effect of intracoronary injection of enriched autologous CD133+ cells to patients with an LVEF less than 50% and following stented acute myocardial infarction. Enrollment for this trial is still ongoing but the first 20 patients have already shown a significant improvement in LVEF after four months of follow-up. The data so far indicates that intracoronary injection of CD133+ bone marrow stem cells is safe and has significant beneficial effects on LVEF. “The data so far indicates that intracoronary injection of CD133+ bone marrow stem cells is safe and has significant beneficial effects on LVEF.” “Preliminary results indicate that the quality of life has improved notably compared to the preoperative data.”
  • 15. 15 ASH 2009 December 5 to 8, 2009, New Orleans, Louisiana, USA. Here, we report on two selected presentations from the ASH meeting. The latter, describing the use of regulatory T cells in a mismatched transplantation setting, was elected for the presidential session. Both presentations were discussed at a press conference. Oral presentation 1: Monday, December 7, 2009; 4:30 p.m. (Ernest N. Morial Convention Center): Highlights:Thedatafrom44AMLpatientsateight participatingcentersdemonstratedthatinfusionof CD34+ -enriched stem cells from a matched related donor results in low transplant-related mortality, low incidence of relapse, and excellent disease-free and overall survival. The low incidences of acute and chronic GvHD in the absence of any post- transplant prophylaxis were particularly encour- aging, as the absence of this complication highly improves the patient’s quality of life. A full-paper publication comparing these data to another transplant study will come out shortly. Adapted from abstract published online at http://ash.confex.com/ash/2009/webprogram/ Paper18537.html. Abstract 655 : Allogeneic hematopoietic cell trans- plantation (HCT) is the most effective means to prevent relapse in patients (pts) with AML in complete remission (CR). However, quality of life and overall survival (OS) are often affected by both acute and chronic graft-versus-host disease (GvHD). GvHD is most effectively prevented by ex vivo T cell depletion (TCD) of the allograft, but has been limited in its use by logistical difficulties, lack of an FDA-approved method, and concerns regarding potential risk of graft rejection, post- transplant infections, and leukemic relapse. Most reportedTCDstudiesrepresentsinglecenters,mul- Meeting minutes HLA-identical sibling-matched, CD34+ -selected, T cell–depleted peripheral blood stem cells following myeloablative conditioning for first or second remission acute myeloid leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303 Steven M. Devine, MD, Robert J. Soiffer, MD, Marcelo C. Pasquini, MD, Shelly Carter, Parameswaran N. Hari, MD, MRCP, MS, Stephanie DeVore, Anthony Stein, Hillard M. Lazarus, MD, Charles Linker, MD, Edward A. Stadtmauer, MD, Carolyn A. Keever-Taylor, PhD , and Richard J O’Reilly, MD
  • 16. 16 CliniMACS Newsletter 1/2010 Meeting minutes tiple disease types, and processing methods with varying degrees of TCD, all of which affect out- come. Therefore we designed a trial using a single processing method providing extensive TCD that did not require post transplant GvHD prophy- laxis involving adult patients with AML in first or second CR. We hypothesized that the undesired side effects of TCD HCT would be reduced if com- bined with a conditioning regimen that was highly immunosuppressive and anti-leukemic. The pri- mary objective was to achieve a disease-free sur- vival (DFS) rate at 6 months (mos) post transplant that exceeded 75%. Secondary objectives included assessments of engraftment, transplant-related mortality (TRM), GvHD, relapse, and perfor- mance of a single TCD method (CD34+ cell selec- tion using the CliniMACS device) at participating centers. From 10/2005 to 12/2008, 47 patients were enrolled and 44 transplanted at 8 different centers. Median age was 48.5 years (range 21–59) with 28 female and 16 male pts. Of 37 AML CR1 patients, 49% had an unfavorable cytogenetic or molecular riskprofile.Theconditioningregimenconsistedof hyperfractionated total body irradiation (1375cGy in 11 fractions) with partial lung shielding, thiote- pa (10 mg/kg), cyclophosphamide (120 mg/kg), and rabbit antithymocyte globulin (2.5 mg/kg). The donors, all HLA-identical siblings, were given G-CSF for mobilization and scheduled to undergo at least two leukapheresis procedures to ensure a graft with a high CD34+ cell content. All allografts were CD34-enriched and were targeted to contain ≥5×10⁶CD34+ cells/kgand1.0×10⁵CD3+ cells/kg. The median CD34+ and CD3+ doses achieved were 8.1×10⁶/kg (range2.4–46.2) and 0.07×10⁵/kg (range 0.01–0.85), respectively. The majority (81%) of patients received the targeted CD34+ cell dose and no patient received 1.0×10⁵ CD3+ cells/kg. No pharmacological GvHD prophylaxis was given post-transplant. There were no significant tox- icities related to infusion of the CD34-enriched allografts. The most common grade 3–5 regimen- related toxicities included grades 3 or 4 mucositis (39%) and grades 3–5 pulmonary abnormalities (11%). Only one patient experienced hepatic veno- occlusive disease. All patients engrafted rapidly with a median time to neutrophil recovery (ANC 500/µL) of 11 days (range 9–19). There was one secondary graft failure. The assessed outcomes are shown below. The absolute peripheral CD4+ cell count remained on average below 200 µL until day +365. Donor cell chimerism increased in the CD3+ cell compart- ment through day +365. There were 14 deaths. The most common causes of death were relapse N=5 and pulmonary toxicity N=4. The median follow- up of survivors is 489 days range 96-776. There was no difference in OS or DFS for pts above or below the median age of 48.5 years. We conclude that TCD HCT–following myeloablative chemo- radiotherapy can be performed in a multicenter setting using a single TCD method without addi- tional post-transplant prophylaxis with excellent DFS and OS‚ consistent engraftment‚ low TRM and low incidence of relapse even in patients with unfavorable risk AML in CR1. The low incidences of acute and chronic GvHD in the absence of post- transplant prophylaxis were particularly encour- aging. A follow-up study of TCD HCT in AML recipients of unrelated donor allografts is being planned by the BMT CTN. Estimate (95% confidence interval) Outcome 100 days 6 months 12 months Acute GvHD II-IV 20.5% (8.7–23.3%) Acute GvHD III-IV 4.5% (0–10.6%) Chronic GvHD 17.7% (5.8–29.6%) Extensive chronic GvHD 7.6% (0–15.7%) TRM 17.8% (5.8–29.8%) Overall relapse 18.2% (5.9–30.5%) Relapse 1st CR 9.6% (0–19.8%) Relapse 2nd CR 64.3% (27.5–100%) DFS 64.0% (46.5–77.1%) DFS 1st CR 72.1% (53.0–84.6%) OS 74.3% (57.3–85.4%)
  • 17. 17 Customer reportMeeting minutes Oral presentation 2: Sunday, December 6, 2009; 2:45 p.m. (Ernest N. Morial Convention Center): Highlights: An innovative strategy using CliniMACS-enriched regulatory T cells (CD4+ /CD25+ ) might improve the outcome of patients, who undergo haploidentical stem cell transplantation. This is the conclusion from an ongoing clinical trial, which was presented byProf.Martelliataplenarysession(abstractbelow) and even discussed at a press conference. Based on successful animal models, this first-in-man phase I/II trial evaluates the impact of regulatory T cells on graft-versus-host disease–prevention and immunological immune reconstitution. Preliminary data of 28 patients demonstrate that by using the CliniMACS to enrich for regulatory T cells, transfusing high numbers of donor T cells, up to 2×106 /kg can be allowed. Remarkably, a very low incidence of graft-versus- host disease was observed in the 26 evaluable patients, whilst speed of post-transplant immune recovery and the incidence of CMV reactivation was improved compared to previous studies. Two patients were not evaluated due to a different protocol. These preliminary results raise hope that with longer follow-up of this treatment method will lead to reduced infection-related mortality and thus improve overall survival. Finally, this study may open up new prospects for the adoptive transfer of T regulatory cells not only in the field of hematology but for other indications, for example, to induce specific immunological tolerance in the field of organ transplantation and autoimmune diseases. Adapted from abstract published online at http://ash.confex.com/ash/2009/webprogram/ Paper18555.html. Transplantation of large numbers of highly purified CD34+ cells from haploidentical relatives isaviablestrategyforthecureofacuteleukaemiaat high risk of relapse (Aversa et al. NEJM 1998; JCO 2005). As extensive T cell depletion is required to prevent GvHD, thevery narrow Tcellrepertoire in the inoculum delays recovery of immune response against pathogens, leading to a high incidence of infection-related deaths. Thus the key challenge is to improve immune recovery by administering allogeneic donor T cells without causing graft- versus-host disease (GvHD). Preclinical studies demonstrated that freshly isolated or ex vivo expanded T regulatory cells (Tregs) could be used to control GvHD-following bone marrow transplantation. The present phase I/II clinical trial evaluated the impact of early infusion of freshlyisolateddonorCD4+ /CD25+ Tregs,followed by an inoculum consisting of donor mature T cells (Tcons) and positively immunoselected CD34+ cells, on GvHD prevention and immunological reconstitution. Twenty-two patients (10 male; 12 female; median age 40.5, range, 21 to 60) with AML (n=17; 8 in CR1 at high risk, 7 in ≥CR2, and 2 in relapse), ALL (n=4; 3 in CR1; 1 in relapse) and 1 with high grade NHL in relapse were enrolled from September 2008 onwards. The conditioning regimen consisted of 8Gy single fraction TBI, thiotepa (4 mg/kg×2), fludarabine (40 mg/m2 ×4), and cyclophosphamide (35 mg/kg×2). All patients receivedCD4+ /CD25+ GMPimmunoselectedTregs Adoptive immunotherapy with Tregs prevents GvHD and favours immune reconstitution after HLA haploidentical transplants for hematological malignancies Mauro Di Ianni, Franca Falzetti, Alessandra Carotti, Adelmo Terenzi, Elisabetta Bonifacio, Yair Reisner, Andrea Velardi, Franco Aversa, and Massimo F Martelli Figure 1: Treatment schedule: After conditioning, patients were infused with escalating doses of Tregs, followed three days later by immune-selected CD34+ cells together with individual doses of donor mature T cells. 8 Gy T B I Thiotepa 4 mg/kg/day Cyclophosphamide 35 mg/kg/day Fludarabine 40 mg/s qm/day Days -3 Conditioning Tcons Tregs CD 34+ No post transplant immuno suppression
  • 18. 18 CliniMACS Newsletter 1/2010 Customer report (CliniMACS, Miltenyi Biotec) (21/22 2×10⁶/kg bw; 1/22 1×10⁶/kg bw). Three days later they received positively immunoselected CD34+ cells (median 8.2×106 /kg, range 5.0–19.1) together with Tcons (16/22 1×106 /kg bw; 4/22 0.5×106 /kg bw; 2/22 did not receive Tcons). Immunoselected CD4+ /CD25+ Tregs (purity 91.5%±4.5) consisted of CD25high 25.6%±11.2; CD25int 57.4%±5.9; CD25low 8.5%±6; FoxP3 64%±1; CD127 14.9%±13.7 (mean±SD). As suggested by in vitro immuno- suppressive assays and by immunophenotypic analysis, the contaminating cells in the Treg fraction were 50% of the CD25int and 100% of the CD25low, so that the infused Tregs:Tcons ratio was established at 1:1.5. No post-transplant prophylaxis against GvHD was used and 20/22 patients were engrafted. Neutrophils reached 1×10⁹/L at a median of 15 days (range; 11 to 39 days). Platelets reached 25×10⁹/L and 50×109 /L at medianof13and15days,respectively(range:11to 48 days, and 13 to 60 days). All engrafted patients showed persistent full donor-type chimerism in peripheral blood and bone marrow. Strikingly, no GvHD was observed in 17/20 valuable patients, 2/20 developed grade I cutaneous self-limited untreated GvHD and 1/20 developed grade III GvHD. This patient had received the fewest Tregs. Six patients died (1 bacterial sepsis, 2 VOD, 1 fungal pneumonia, 1 CNS aspergillosis, and 1 GvHD/systemic toxoplasmosis). In contrast with our previous experience, the speed of immune recovery was enhanced. The CD4 and the CD8 counts reached, respectively, 50/µL medianly on days 34 (range: 19 to 63 days) and 24 (range: 15 to 87); 100/µL medianly on days 47 (range: 28 to 100 days) and 34 (range: 19 to 95); 200/µL on days 70 (range: 41 to 146 days) and 61 (range: 21 to 95). We also observed a rapid development of a wide T cell repertoire and detection of high frequencies of specific CD4+ and CD8+ for opportunistic pathogens such as Aspergillus, Candida, CMV, ADV, HSV, VZV, and Toxoplasma. In KIR ligand–mismatched transplants, speed of NK cell reconstitution/maturation and size of donor versus recipient alloreactive NK cell repertoires were preserved (Ruggeri et al. Science 2002). In conclusion, in the setting of haploidentical transplantation, infusion of freshly purified Tregs makes administration of a high dose of T cells feasible for the first time. This strategy provides a long-term protection from GvHD and robust immune reconstitution. Treg-based cellular therapy may represent an innovative strategy to improve the outcome of haploidentical transplants. Meeting minutes
  • 19. 19 Meeting minutes EBMT 2010 March 21 to 24, 2010, Vienna, Austria Satellite symposium: Cellular therapy – the next generation. A very interactive symposium saw the latest in cellular therapy being discussed with highlights on allogeneic stem cell transplants, haploidentical stem cell transplants, T cell and NK cell therapy. Adoptive immunotherapy with Tregs and Tcons hastens immune reconstitution without triggering GvHD in HLA haploidentical transplantation Massimo F. Martelli, Italy Preclinical models have indicated that CD4+ /CD25+ regulatory T cells (Tregs) aid graft- versus-tumor activity while suppressing GvHD. The speaker described the immuno-magnetic enrichment of Tregs in a fully automated system that yielded 2–4×10⁶/kg Tregs. Treating leukemia patientswithfreshlypurifiedTregsbeforeinfusing highdosesofconventionalTcellsinahaplosetting resulted in a low incidence of GvHD but there was no cross-inhibition of Tcons responses to pathogens. By enhancing immune reconstitution, adoptive transfer of Tregs and Tcons significantly reduced the risk of CMV reactivation. An allogeneic stem cell transplant is usually required in acute lymphoblastic leukemia patients at risk of relapse. The probability of finding a matched sibling donor is low so a haploidentical stem cell graft is often the only option, with the associated problem of graft-versus-host disease (GvHD). This problem has been countered in the past by depletion of T cells but this, in turn, has resulted in a high incidence of infection-related complications. The principal objective of clinical research is thus to improve immune recovery without causing GvHD. “By enhancing immune reconstitution, adoptive transfer of Tregs and Tcons significantly reduce the risk of CMV reactivation.”
  • 20. 20 CliniMACS Newsletter 1/2010 Transplantation of CD3/CD19 depleted grafts in pediatric patients with hematological malignancies and non-malignant disorders Peter Bader and Thomas Klingebiel, Germany period of between 1 and 61 months. Transplant- related mortality was caused by toxicity (n=4), GvHD (n=1) and adenoviral infection (n=1) in four patients with malignant disease. Only those leukemia patients who were in remission at the time of transplantation had a 70–80% probability of a 3-year survival. NK receptor-ligand mismatch also increased the probability of survival amongst all patients. T cell and NK regeneration was apparent within 40 days of transplantation. The speaker concluded that the haploidentical engraftment in adolescents and young adults with leukemiawasfeasibleandeffective,showedreduced acute toxicity and rapid immune regeneration. Successful haploidentical stem cell transplan- tation is associated with an aggressive regimen of immune depletion and very high doses of puri- fied peripheral stem cells containing insignifi- cant numbers of T or B cells. One of the recent advancements in stem cell transplantation was the realization that the use of alloreactive NK cells reduces GvHD, enhances immune reconstitution and aids graft-versus-leukemia activity. The speaker reviewed a prospective trial involving 60 patients (10 with non-malignant disease) aged from 0.6 to 27.2 years who were transplanted with stem cells depleted immuno-magnetically with CD3/19 MicroBeads and assessed over a follow-up T cell immunotherapy for viral complications post-SCT Tobias Feuchtinger, Germany NK cell therapy in hematologic malignancies Wing Leung, USA Viral infections cause morbidity and mortality followinghematopoieticstemcelltransplantation. An effective T cell response appears to be essential for clearance of the virus, and adoptive transfer of pathogen-specific donor T cells has become increasingly important for patients with viral infections who lack specific T cell responses. The speaker described a trial of adoptive T cell transfer in 59 patients (41 with leukemia) who had previously received haplo, mismatched, or matchedgraftsandwhoweresufferingfromeither The speaker noted the four most significant adverse events associated with bone marrow transplantation: graft-versus-host disease, disease relapse, infection, and graft rejection. An ad- vantage of NK transplantation is that all these parameters are reduced. The NK donor is best determinedbycharacterizationofthekillerIg-like receptor (KIR) whereby a KIR match appears to increase the likelihood of relapse and a KIR mismatch to reduce it. A large-scale enrichment adenovirus or cytomegalovirus infection. Donor peripheral blood mononuclear cells (PBMC) were stimulated with appropriate viral antigen for 16 hours before CD4+ and CD8+ cells were isolated and infused into the patient. Follow-up showed that virological and clinical improvement correlated with in vivo CMV and ADV T cell responses. It appears that adoptive T cell transfer of antigen-specific T cells represents an effective second-line treatment for viral complications after SCT. of NK cells was described, which resulted in high CD56+ cell purity and less than 1% T and B cells. These NK cells showed extensive proliferative activity in vivo. A BMT and KIR mismatch NK cell transplant of infant leukemia patients improved survival from 0% to 65%. A trial of single parental KIR mismatch NK grafts with ten AML patients who had completed standard chemotherapy resulted in an estimated survival of 50–60% over a period of four years. “My Dad’s NK cells are great. Now I’m in remission.” Meeting minutes “… haploidentical engraftment in adolescents and young adults with leukemia was feasible and effective, showed reduced acute toxicity and rapid immune regeneration.” “… adoptive T cell transfer of antigen-specific T cell represents an effective second-line treatment for viral complications after SCT.”
  • 21. 21 Hematopoietic stem cell transplantation for severe autoimmune diseases – a program coming of age Jacob M. Van Laar, UK The key treatment goal in autoimmune disease is prevention of end-organ damage but many conditions remain incurable despite new treat- ment paradigms and biologicals. Two of the aims of hematopoietic stem cell transplantation (HSCT) are to induce and maintain regulation and to abrogate inflammation. The level of progression-free survival following HSCT is related to the underlying disease. The outcome of HSCT in MS is affected by age and number of years since diagnosis: younger and sooner has the best prognosis following HSCT. HSCT in RA suppresses inflammation but is not curative, whereas in SLE, HSCT results in a rapid improvement in clinical parameters. There are a large number of trials ongoing within Europe to assesstherisk-benefitofHSCTinscleroderma,SLE, MS, and Crohn’s disease. The randomized ASTIS (autologousstemcelltransplantationinternational scleroderma) trial compares CliniMACS CD34 – selected SCT versus cyclophosphamide therapy in 150 patients. Here, a higher event-free survival is expected in the SCT arm in comparison to the control arm. Current evidence suggests that HSCT is a treatment option for carefully selected patients with a high-risk, but not end-stage, severe autoimmune disease for whom no conventional therapy exists. Meeting minutes “… HSCT is a treatment option for carefully selected patients with a high-risk, but not end-stage, severe autoimmune disease for whom no conventional therapy exists.”
  • 22. 22 CliniMACS Newsletter 1/2010 FAQs Which types of tubing sets can be used for a CD3 or a combined CD3/CD19 depletion*? Both the CliniMACS Depletion Tubing Set and the CliniMACS Tubing Set LS are suitable for a CD3 or CD3/CD19 depletion. The graph below illustrates that for products containing up to 4.5×10⁹ labeled cells the processing time for both tubing set types is comparable. FAQs However, with higher numbers of labeled cells the CliniMACS Depletion Tubing Set is clearly time-saving (example for 20×10⁹ labeled cells: The depletion process using the CliniMACS Depletion Tubing Set takes 1.25 hours versus 5 hours if using the CliniMACS Tubing Set LS). 21–40×10⁹ labeled cells can only be processed in one procedure when using the CliniMACS Depletion Tubing Set. We would greatly appreciate your feedback. Please e-mail us at macs@miltenyibiotec.de Processing time LSTS versus DTS Total number of labeled cells [×10⁶] Processing time LSTS versus DTS 0 50 100 150 200 250 900 2.250 3.375 4.500 9.000 13.500 18.000 total number of labeled cells [x10 6 ] Process time [min] LSTS DTS Processtime[min]
  • 23. 23 FAQs What can be done to optimize a CD3 or a combined depletion*? · Processing apheresis products directly after harvest. · Minimizing the number of potentially interfering apheresis-related factors (e.g. granulocytes, platelets) effectively. · Using Fc-receptor blocking prior to CD3 labeling in order to minimize non-specific binding. · Ensuring that all cells are in contact with the reagent during labeling. · Safely determining the sample parameters for the CliniMACS procedure. Considering all CD3+ and CD19+ cells for input of “frequency of labeled cells”, not only real T and B cells. · Determining the frequency of labeled cells directly before the labeling procedure is started. · Determining the remaining T and B cells with an appropriate flow cytometry protocol (rare cell analysis), e.g., Schumm, Cytotherapy 2006, Koehl, Int. J. Hematol. 2008, or Miltenyi Biotec special protocol 54. Do the CryoMACS® Freezing Bags contain any latex? No, all CryoMACS Freezing Bags are latex-free. MACS® GMP Products provide integrated solutions for cell separation and cell culture. Which products are currently available? Currently available MACS GMP Products Peptides/proteins: MACS GMP HCMV pp65 – Recombinant Protein (# 200-076-100) MACS GMP PepTivator HCMV pp65 (# 170-076-109) MACS GMP PepTivator AdV5 Hexon (# 170-076-106) Cytokines: MACS GMP Recombinant Human GM-CSF (# 170-076-112) MACS GMP Recombinant Human FGF-2 (# 170-076-107) MACS GMP Recombinant Human IL-1β (# 170-076-102) MACS GMP Recombinant Human IL-3 (# 170-076-110) MACS GMP Recombinant Human IL-4 (# 170-076-101) MACS GMP Recombinant Human IL-6 (# 170-076-104) MACS GMP Recombinant Human TNF-α (# 170-076-103) Bothproductgroupswillbecontinuallyexpanded. Different types of cell culture bags intended for in vitro expansion, differentiation, or cultivation are already part of the MACS GMP Product portfolio with cell culture media to be added later. * The CliniMACS CD3/CD19 Reagent combination is not available in the USA.
  • 24. 24 CliniMACS Newsletter 1/2010 Speed up your DC vaccination Blood dendritic cell–based immune therapy CliniMACS® Reagents Myeloid DCs CliniMACS CD1c (BDCA-1)/CD19 Complete Kit* Plasmacytoid DCs CliniMACS CD304 (BDCA-4) Reagent* The CliniMACS® System components: Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. CliniMACS MicroBeads are for research use only and not for use in humans. MACS and CliniMACS are registered trademarks of Miltenyi Biotec GmbH. Copyright © 2010 Miltenyi Biotec GmbH. All rights reserved. Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact. miltenyibiotec.com Benefit from CliniMACS® Technology • Highly pure • Clinical-grade dendritic cells (DC) • Directly from blood * Available for research use only in the USA.
  • 25. 25 Notes:
  • 26. 26 CliniMACS Newsletter 1/2010 Calendar Conference calendar Meet us at the booth! Date Congress Webpage December 4-7, 2010 ASH-American Society of Hematology, Orlando, FL, USA www.hematology.org January 24-27, 2011 Arab Health 2011, Dubai www.arabhealthonline.com February 17-21, 2011 BMT Tandem Meetings (ASBMT, CIBMTR), Honolulu, Hawaii, USA www.asbmt.org March 24-25, 2011 Cellular Therapy 2011 - 6th Intl Symposium on the Clinical Use of Cellular Products, Erlangen, Germany www.cellular-therapy.de April 3-6, 2011 EBMT-European Group of Blood and Marrow Transplantation, Paris, France www.congrex.ch/ebmt2011
  • 27. 27 Fax reply form Fax reply form CliniMACS® Newsletter Vol. 10 No. 1/2010 Please mark below and fax to: Miltenyi Biotec, Marketing Department, Attn.: Brigitte Borchert Fax no. +49 2204 85197 My research focus is Surname, First name Institute, Department Street City/Postal code/Country Phone Fax E-mail EBMT 2010 130-095-378 Abstract booklet, Miltenyi Biotec symposium “Cellular therapies – the next generation” ESC Meeting 2009 130-094-871 (booklet) 130-094-872 (DVD) Abstract booklet and DVD with all presentations, Miltenyi Biotec symposium “Study concepts and routes of administration in autologous stem cell therapy” Product Catalog 2011/2012 130-096-073 MACS GMP Products Product information MACS Products for DC work Product information Please check the box if you wish to receive further information. Your local Miltenyi Biotec representative is available to visit your site and discuss our products in more detail.
  • 28. I CliniMACS Newsletter 1/2010 Customer report 130-096-025 www.miltenyibiotec.com With compliments from: Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact. Copyright © 2010 Miltenyi Biotec GmbH. All rights reserved. Distributors Subsidiaries Argentina Lab Systems S.A. Phone +54 11 4572 8458 Belarus JLTD Medbioscience Phone +375 172 67 70 25 Bosnia and Herzegovina Superlab** Phone +381 11 22 22 222 Brazil Ambriex S/A Phone +55 11 3665 1090 Bulgaria Epsilon Epsilon Medical S.A. Phone +30 210 6996 191 Canada Miltenyi Biotec Inc. Phone +1 530 888 8871 Chile UB Ursula Biggemann y Cía Ltda. Phone +56 2 334 9282 Colombia Rochem Biocare Colombia S.A.* Phone +57 1 446 4343 Croatia Biovit d.o.o. Phone +385 42 260 001 Cyprus Epsilon Epsilon Medical S.A. Phone +30 210 6996 191 Czech Republic BIOHEM spol. s.r.o. Phone +421 32 6505005 Denmark Fisher Scientific* Phone +45 70 2799 20 Ecuador Frisonex Phone +593 22 267 554 Egypt Al Yamama Phone +962 6 4655 166 Estonia Fisher Scientific* Phone +358 9 802 766 Finland Fisher Scientific* Phone +358 9 802 766 Greece Epsilon Epsilon Medical S. A. Phone +30 210 6996 191 Hong Kong Miltenyi Biotec Asia Pacific Pte Ltd. Phone +65 6238 8183 Hungary Frank Diagnosztika Kft. Phone +361 250 1813 Phone +361 388 3114 Iceland Fisher Scientific* Phone +45 70 27 99 20 India Miltenyi Biotec Asia Pacific Pte Ltd. Phone +65 6238 8183 Indonesia Miltenyi Biotec Asia Pacific Pte Ltd. Phone +65 6238 8183 Israel Y. A. Almog Diagnostic Medical Equipment Ltd. Phone +972 3 977 33 90 Jordan Al Yamama Phone +962 6 4655 166 Latvia Fisher Scientific* Phone +358 9 802 766 Lebanon Al Yamama Phone +962 6 4655166 Lithuania Fisher Scientific* Phone +358 9 802 766 Malaysia Miltenyi Biotec Asia Pacific Pte Ltd. Phone +65 6238 8183 Mexico Uniparts, S.A. DE C. V. Phone +52 81 83 366812 Montenegro Superlab** Phone +381 11 22 22 222 New Zealand Miltenyi Biotec Australia Pty. Ltd. Phone +61 02 8877 7400 Northern Ireland Vector Scientific Phone +44 2890 448800 Norway Fisher Scientific* Phone +47 22 95 59 59 Oman Al Yamama Phone +962 6 465 5166 Pakistan Miltenyi Biotec Asia Pacific Pte Ltd.* Phone +65 6238 8183 Allmed Solutions** Phone +92 21 34857624 Peru Immunochem SAC Phone +51 1 440 9678 Phillipines Miltenyi Biotec Asia Pacific Pte.Ltd.* Phone +65 6238 8183 Macare Medical, Inc.** Phone +63 2 913 5937 Poland Medianus Sp. z o.o. Phone +48 12 665 3131 Portugal Citomed Lda. Phone +351 218 421 430 Qatar Al Yamama Phone +962 6 465 5166 Romania Novaintermed SRL Phone +40 21 230 74 30 Russia Biocommerce Ltd. Phone +7 495 414 68 15 Spektronika Ltd.* Phone +7 495 221 6763 Saudi Arabia Fawaz Trading Est. Phone +966 1 4038510 Serbia Superlab** Phone +381 11 22 22 222 Slovak Republic BIOHEM spol s.r.o. Phone +421 32 6505005 South Africa Biocom Biotech Phone +27 82 484 7934 South Korea Medilab Korea Co. Ltd. Phone +82 2 424 6367 Sweden Fisher Scientific* Phone +46 31 352 32 30 Taiwan J H Technology Co. Ltd.* Phone +886 2 879 127 69 Operon BioPharma Co., Ltd.** Phone +886 2 2394 0801 Thailand Miltenyi Biotec Asia Pacific Pte. Ltd.* Phone +65 6238 8183 Venus Technology Co. Ltd.** Phone +66 2 9356 761 Turkey MAK Sağlik Ürünleri İth. İtr. Tic San. Itd. Şti Phone +90 312 4733 311 Phone +90 216 360 62 74 Ukraine LLC Ecomed München Haus Phone +38 048 716 6025 United Arab Emirates Al Yamama Phone +962 6 465 5166 Venezuela Biologia Molecular y Biotecnologia Phone +58 212 975 2617 * Research products only ** Clinical products only Germany/Austria/ Switzerland Miltenyi Biotec GmbH Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach Germany Phone +49 2204 8306-0 Fax +49 2204 85197 macs@miltenyibiotec.de USA/Canada Miltenyi Biotec Inc. 2303 Lindbergh Street Auburn, CA 95602, USA Phone 800 FOR MACS Phone +1 530 888 8871 Fax +1 530 888 8925 macs@miltenyibiotec.com Australia Miltenyi Biotec Australia Pty. Ltd. Unit 16A, 2 Eden Park Drive North Ryde, NSW 2113 Australia Phone +61 2 8877 7400 Fax +61 2 9889 5044 macs@miltenyibiotec.com.au Benelux Miltenyi Biotec B.V. Schipholweg 68 H, 2316 Leiden The Netherlands macs@miltenyibiotec.nl Customer service Netherlands Phone 0800 4020120 Fax 0800 4020100 Customer service Belgium Phone 0800 94016 Fax 0800 99626 Customer service Luxembourg Phone 800 24971 Fax 800 24984 China Miltenyi Biotec Trading (Shanghai) Co., Ltd. Shanghai Office Rm. 2309-2310, No. 319 Xianxia Rd. Shanghai 200051, P.R. China Phone +86 21 62351005 Fax +86 21 62350953 macs@miltenyibiotec.com.cn France Miltenyi Biotec SAS 10 rue Mercoeur 75011 Paris, France Phone +33 1 56 98 16 16 Fax +33 1 56 98 16 17 macs@miltenyibiotec.fr Italy Miltenyi Biotec S.r.l. Via Persicetana, 2/D 40012 Calderara di Reno (BO) Italy Phone +39 051 6 460 411 Fax +39 051 6 460 499 macs@miltenyibiotec.it Japan Miltenyi Biotec K.K. Nittsu-Eitai Building 5F 16-10 Fuyuki, Koto-ku, Tokyo 135-0041, Japan Phone +81 3 5646 8910 Fax +81 3 5646 8911 macs@miltenyibiotec.jp Singapore Miltenyi Biotec Asia Pacific Pte Ltd. 100 Beach Road #28-06 to 28-08 Shaw Tower Singapore 189702 Phone +65 6238 8183 Fax +65 6238 0302 macs@miltenyibiotec.com.sg Spain Miltenyi Biotec S.L. C/Luis Buñuel 2 Ciudad de la Imagen 28223 Pozuelo de Alarcón (Madrid), Spain Phone +34 91 512 12 90 Fax +34 91 512 12 91 macs@miltenyibiotec.es United Kingdom Miltenyi Biotec Ltd. Almac House, Church Lane Bisley Surrey GU24 9DR, UK Phone +44 1483 799 800 Fax +44 1483 799 811 macs@miltenyibiotec.co.uk